世界の神経栄養性角膜炎市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Neurotrophic Keratitis Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5884 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、神経栄養性角膜炎の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（治療薬、外科的介入）、用途別市場規模（病院、クリニック）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・神経栄養性角膜炎の市場動向 ・企業の競争状況、市場シェア ・神経栄養性角膜炎の種類別市場規模と予測2016-2027（治療薬、外科的介入） ・神経栄養性角膜炎の用途別市場規模と予測2016-2027（病院、クリニック） ・神経栄養性角膜炎の北米市場規模2016-2027（アメリカ、カナダ） ・神経栄養性角膜炎の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・神経栄養性角膜炎のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・神経栄養性角膜炎の中南米市場規模2016-2027（メキシコ、ブラジル） ・神経栄養性角膜炎の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Dompe farmaceutici S.p.A.,、Allergan,、ReGenTree, LLC, Alcon,、Bausch & Lomb Incorporated (Bausch Health Companies Inc.),、CONTACARE,、OHTO Pharmaceutical Co., Ltd.,、Pfizer, Inc.,、Neuroptika、Santen Pharmaceutical Co., Ltd.,、Johnson & Johnson,、Grand Pharma (China) Co., Ltd., and、Zhejiang CONBA Pharmaceutical Co., Ltd.） ・結論

Neurotrophic keratitis (NK) is a degenerative disease of the cornea caused by damage of the trigeminal nerve, which results in impairment of corneal sensitivity, spontaneous corneal epithelium breakdown, poor corneal healing and development of corneal ulceration, melting and perforation.

Market Analysis and Insights: Global Neurotrophic Keratitis Market
The global Neurotrophic Keratitis market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neurotrophic Keratitis market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neurotrophic Keratitis market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neurotrophic Keratitis market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neurotrophic Keratitis market.

Global Neurotrophic Keratitis Scope and Market Size
Neurotrophic Keratitis market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neurotrophic Keratitis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Drugs
Surgical Intervention

Segment by Application
Hospital
Clinic

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Dompe farmaceutici S.p.A.,
Allergan,
ReGenTree, LLC, Alcon,
Bausch & Lomb Incorporated (Bausch Health Companies Inc.),
CONTACARE,
OHTO Pharmaceutical Co., Ltd.,
Pfizer, Inc.,
Neuroptika
Santen Pharmaceutical Co., Ltd.,
Johnson & Johnson,
Grand Pharma (China) Co., Ltd., and
Zhejiang CONBA Pharmaceutical Co., Ltd.

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurotrophic Keratitis Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Drugs
1.2.3 Surgical Intervention
1.3 Market by Application
1.3.1 Global Neurotrophic Keratitis Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Neurotrophic Keratitis Market Perspective (2016-2027)
2.2 Neurotrophic Keratitis Growth Trends by Regions
2.2.1 Neurotrophic Keratitis Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neurotrophic Keratitis Historic Market Share by Regions (2016-2021)
2.2.3 Neurotrophic Keratitis Forecasted Market Size by Regions (2022-2027)
2.3 Neurotrophic Keratitis Industry Dynamic
2.3.1 Neurotrophic Keratitis Market Trends
2.3.2 Neurotrophic Keratitis Market Drivers
2.3.3 Neurotrophic Keratitis Market Challenges
2.3.4 Neurotrophic Keratitis Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Neurotrophic Keratitis Players by Revenue
3.1.1 Global Top Neurotrophic Keratitis Players by Revenue (2016-2021)
3.1.2 Global Neurotrophic Keratitis Revenue Market Share by Players (2016-2021)
3.2 Global Neurotrophic Keratitis Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neurotrophic Keratitis Revenue
3.4 Global Neurotrophic Keratitis Market Concentration Ratio
3.4.1 Global Neurotrophic Keratitis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurotrophic Keratitis Revenue in 2020
3.5 Neurotrophic Keratitis Key Players Head office and Area Served
3.6 Key Players Neurotrophic Keratitis Product Solution and Service
3.7 Date of Enter into Neurotrophic Keratitis Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Neurotrophic Keratitis Breakdown Data by Type
4.1 Global Neurotrophic Keratitis Historic Market Size by Type (2016-2021)
4.2 Global Neurotrophic Keratitis Forecasted Market Size by Type (2022-2027)

5 Neurotrophic Keratitis Breakdown Data by Application
5.1 Global Neurotrophic Keratitis Historic Market Size by Application (2016-2021)
5.2 Global Neurotrophic Keratitis Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Neurotrophic Keratitis Market Size (2016-2027)
6.2 North America Neurotrophic Keratitis Market Size by Type
6.2.1 North America Neurotrophic Keratitis Market Size by Type (2016-2021)
6.2.2 North America Neurotrophic Keratitis Market Size by Type (2022-2027)
6.2.3 North America Neurotrophic Keratitis Market Size by Type (2016-2027)
6.3 North America Neurotrophic Keratitis Market Size by Application
6.3.1 North America Neurotrophic Keratitis Market Size by Application (2016-2021)
6.3.2 North America Neurotrophic Keratitis Market Size by Application (2022-2027)
6.3.3 North America Neurotrophic Keratitis Market Size by Application (2016-2027)
6.4 North America Neurotrophic Keratitis Market Size by Country
6.4.1 North America Neurotrophic Keratitis Market Size by Country (2016-2021)
6.4.2 North America Neurotrophic Keratitis Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Neurotrophic Keratitis Market Size (2016-2027)
7.2 Europe Neurotrophic Keratitis Market Size by Type
7.2.1 Europe Neurotrophic Keratitis Market Size by Type (2016-2021)
7.2.2 Europe Neurotrophic Keratitis Market Size by Type (2022-2027)
7.2.3 Europe Neurotrophic Keratitis Market Size by Type (2016-2027)
7.3 Europe Neurotrophic Keratitis Market Size by Application
7.3.1 Europe Neurotrophic Keratitis Market Size by Application (2016-2021)
7.3.2 Europe Neurotrophic Keratitis Market Size by Application (2022-2027)
7.3.3 Europe Neurotrophic Keratitis Market Size by Application (2016-2027)
7.4 Europe Neurotrophic Keratitis Market Size by Country
7.4.1 Europe Neurotrophic Keratitis Market Size by Country (2016-2021)
7.4.2 Europe Neurotrophic Keratitis Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Neurotrophic Keratitis Market Size (2016-2027)
8.2 Asia-Pacific Neurotrophic Keratitis Market Size by Type
8.2.1 Asia-Pacific Neurotrophic Keratitis Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neurotrophic Keratitis Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neurotrophic Keratitis Market Size by Type (2016-2027)
8.3 Asia-Pacific Neurotrophic Keratitis Market Size by Application
8.3.1 Asia-Pacific Neurotrophic Keratitis Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neurotrophic Keratitis Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neurotrophic Keratitis Market Size by Application (2016-2027)
8.4 Asia-Pacific Neurotrophic Keratitis Market Size by Region
8.4.1 Asia-Pacific Neurotrophic Keratitis Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neurotrophic Keratitis Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Neurotrophic Keratitis Market Size (2016-2027)
9.2 Latin America Neurotrophic Keratitis Market Size by Type
9.2.1 Latin America Neurotrophic Keratitis Market Size by Type (2016-2021)
9.2.2 Latin America Neurotrophic Keratitis Market Size by Type (2022-2027)
9.2.3 Latin America Neurotrophic Keratitis Market Size by Type (2016-2027)
9.3 Latin America Neurotrophic Keratitis Market Size by Application
9.3.1 Latin America Neurotrophic Keratitis Market Size by Application (2016-2021)
9.3.2 Latin America Neurotrophic Keratitis Market Size by Application (2022-2027)
9.3.3 Latin America Neurotrophic Keratitis Market Size by Application (2016-2027)
9.4 Latin America Neurotrophic Keratitis Market Size by Country
9.4.1 Latin America Neurotrophic Keratitis Market Size by Country (2016-2021)
9.4.2 Latin America Neurotrophic Keratitis Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Neurotrophic Keratitis Market Size (2016-2027)
10.2 Middle East & Africa Neurotrophic Keratitis Market Size by Type
10.2.1 Middle East & Africa Neurotrophic Keratitis Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neurotrophic Keratitis Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neurotrophic Keratitis Market Size by Type (2016-2027)
10.3 Middle East & Africa Neurotrophic Keratitis Market Size by Application
10.3.1 Middle East & Africa Neurotrophic Keratitis Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neurotrophic Keratitis Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neurotrophic Keratitis Market Size by Application (2016-2027)
10.4 Middle East & Africa Neurotrophic Keratitis Market Size by Country
10.4.1 Middle East & Africa Neurotrophic Keratitis Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neurotrophic Keratitis Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Dompe farmaceutici S.p.A.,
11.1.1 Dompe farmaceutici S.p.A., Company Details
11.1.2 Dompe farmaceutici S.p.A., Business Overview
11.1.3 Dompe farmaceutici S.p.A., Neurotrophic Keratitis Introduction
11.1.4 Dompe farmaceutici S.p.A., Revenue in Neurotrophic Keratitis Business (2016-2021)
11.1.5 Dompe farmaceutici S.p.A., Recent Development
11.2 Allergan,
11.2.1 Allergan, Company Details
11.2.2 Allergan, Business Overview
11.2.3 Allergan, Neurotrophic Keratitis Introduction
11.2.4 Allergan, Revenue in Neurotrophic Keratitis Business (2016-2021)
11.2.5 Allergan, Recent Development
11.3 ReGenTree, LLC, Alcon,
11.3.1 ReGenTree, LLC, Alcon, Company Details
11.3.2 ReGenTree, LLC, Alcon, Business Overview
11.3.3 ReGenTree, LLC, Alcon, Neurotrophic Keratitis Introduction
11.3.4 ReGenTree, LLC, Alcon, Revenue in Neurotrophic Keratitis Business (2016-2021)
11.3.5 ReGenTree, LLC, Alcon, Recent Development
11.4 Bausch & Lomb Incorporated (Bausch Health Companies Inc.),
11.4.1 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Company Details
11.4.2 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Business Overview
11.4.3 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Neurotrophic Keratitis Introduction
11.4.4 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Revenue in Neurotrophic Keratitis Business (2016-2021)
11.4.5 Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Recent Development
11.5 CONTACARE,
11.5.1 CONTACARE, Company Details
11.5.2 CONTACARE, Business Overview
11.5.3 CONTACARE, Neurotrophic Keratitis Introduction
11.5.4 CONTACARE, Revenue in Neurotrophic Keratitis Business (2016-2021)
11.5.5 CONTACARE, Recent Development
11.6 OHTO Pharmaceutical Co., Ltd.,
11.6.1 OHTO Pharmaceutical Co., Ltd., Company Details
11.6.2 OHTO Pharmaceutical Co., Ltd., Business Overview
11.6.3 OHTO Pharmaceutical Co., Ltd., Neurotrophic Keratitis Introduction
11.6.4 OHTO Pharmaceutical Co., Ltd., Revenue in Neurotrophic Keratitis Business (2016-2021)
11.6.5 OHTO Pharmaceutical Co., Ltd., Recent Development
11.7 Pfizer, Inc.,
11.7.1 Pfizer, Inc., Company Details
11.7.2 Pfizer, Inc., Business Overview
11.7.3 Pfizer, Inc., Neurotrophic Keratitis Introduction
11.7.4 Pfizer, Inc., Revenue in Neurotrophic Keratitis Business (2016-2021)
11.7.5 Pfizer, Inc., Recent Development
11.8 Neuroptika
11.8.1 Neuroptika Company Details
11.8.2 Neuroptika Business Overview
11.8.3 Neuroptika Neurotrophic Keratitis Introduction
11.8.4 Neuroptika Revenue in Neurotrophic Keratitis Business (2016-2021)
11.8.5 Neuroptika Recent Development
11.9 Santen Pharmaceutical Co., Ltd.,
11.9.1 Santen Pharmaceutical Co., Ltd., Company Details
11.9.2 Santen Pharmaceutical Co., Ltd., Business Overview
11.9.3 Santen Pharmaceutical Co., Ltd., Neurotrophic Keratitis Introduction
11.9.4 Santen Pharmaceutical Co., Ltd., Revenue in Neurotrophic Keratitis Business (2016-2021)
11.9.5 Santen Pharmaceutical Co., Ltd., Recent Development
11.10 Johnson & Johnson,
11.10.1 Johnson & Johnson, Company Details
11.10.2 Johnson & Johnson, Business Overview
11.10.3 Johnson & Johnson, Neurotrophic Keratitis Introduction
11.10.4 Johnson & Johnson, Revenue in Neurotrophic Keratitis Business (2016-2021)
11.10.5 Johnson & Johnson, Recent Development
11.11 Grand Pharma (China) Co., Ltd., and
11.11.1 Grand Pharma (China) Co., Ltd., and Company Details
11.11.2 Grand Pharma (China) Co., Ltd., and Business Overview
11.11.3 Grand Pharma (China) Co., Ltd., and Neurotrophic Keratitis Introduction
11.11.4 Grand Pharma (China) Co., Ltd., and Revenue in Neurotrophic Keratitis Business (2016-2021)
11.11.5 Grand Pharma (China) Co., Ltd., and Recent Development
11.12 Zhejiang CONBA Pharmaceutical Co., Ltd.
11.12.1 Zhejiang CONBA Pharmaceutical Co., Ltd. Company Details
11.12.2 Zhejiang CONBA Pharmaceutical Co., Ltd. Business Overview
11.12.3 Zhejiang CONBA Pharmaceutical Co., Ltd. Neurotrophic Keratitis Introduction
11.12.4 Zhejiang CONBA Pharmaceutical Co., Ltd. Revenue in Neurotrophic Keratitis Business (2016-2021)
11.12.5 Zhejiang CONBA Pharmaceutical Co., Ltd. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Neurotrophic Keratitis Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Drugs
Table 3. Key Players of Surgical Intervention
Table 4. Global Neurotrophic Keratitis Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Neurotrophic Keratitis Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Neurotrophic Keratitis Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Neurotrophic Keratitis Market Share by Regions (2016-2021)
Table 8. Global Neurotrophic Keratitis Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Neurotrophic Keratitis Market Share by Regions (2022-2027)
Table 10. Neurotrophic Keratitis Market Trends
Table 11. Neurotrophic Keratitis Market Drivers
Table 12. Neurotrophic Keratitis Market Challenges
Table 13. Neurotrophic Keratitis Market Restraints
Table 14. Global Neurotrophic Keratitis Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Neurotrophic Keratitis Market Share by Players (2016-2021)
Table 16. Global Top Neurotrophic Keratitis Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurotrophic Keratitis as of 2020)
Table 17. Ranking of Global Top Neurotrophic Keratitis Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Neurotrophic Keratitis Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Neurotrophic Keratitis Product Solution and Service
Table 21. Date of Enter into Neurotrophic Keratitis Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Neurotrophic Keratitis Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Neurotrophic Keratitis Revenue Market Share by Type (2016-2021)
Table 25. Global Neurotrophic Keratitis Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Neurotrophic Keratitis Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Neurotrophic Keratitis Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Neurotrophic Keratitis Revenue Market Share by Application (2016-2021)
Table 29. Global Neurotrophic Keratitis Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Neurotrophic Keratitis Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Neurotrophic Keratitis Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Neurotrophic Keratitis Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Neurotrophic Keratitis Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Neurotrophic Keratitis Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Neurotrophic Keratitis Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Neurotrophic Keratitis Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Neurotrophic Keratitis Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Neurotrophic Keratitis Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Neurotrophic Keratitis Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Neurotrophic Keratitis Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Neurotrophic Keratitis Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Neurotrophic Keratitis Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Neurotrophic Keratitis Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Neurotrophic Keratitis Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Neurotrophic Keratitis Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Neurotrophic Keratitis Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Neurotrophic Keratitis Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Neurotrophic Keratitis Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Neurotrophic Keratitis Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Neurotrophic Keratitis Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Neurotrophic Keratitis Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Neurotrophic Keratitis Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Neurotrophic Keratitis Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Neurotrophic Keratitis Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Neurotrophic Keratitis Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Neurotrophic Keratitis Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Neurotrophic Keratitis Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Neurotrophic Keratitis Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Neurotrophic Keratitis Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Neurotrophic Keratitis Market Size by Country (2022-2027) & (US$ Million)
Table 61. Dompe farmaceutici S.p.A., Company Details
Table 62. Dompe farmaceutici S.p.A., Business Overview
Table 63. Dompe farmaceutici S.p.A., Neurotrophic Keratitis Product
Table 64. Dompe farmaceutici S.p.A., Revenue in Neurotrophic Keratitis Business (2016-2021) & (US$ Million)
Table 65. Dompe farmaceutici S.p.A., Recent Development
Table 66. Allergan, Company Details
Table 67. Allergan, Business Overview
Table 68. Allergan, Neurotrophic Keratitis Product
Table 69. Allergan, Revenue in Neurotrophic Keratitis Business (2016-2021) & (US$ Million)
Table 70. Allergan, Recent Development
Table 71. ReGenTree, LLC, Alcon, Company Details
Table 72. ReGenTree, LLC, Alcon, Business Overview
Table 73. ReGenTree, LLC, Alcon, Neurotrophic Keratitis Product
Table 74. ReGenTree, LLC, Alcon, Revenue in Neurotrophic Keratitis Business (2016-2021) & (US$ Million)
Table 75. ReGenTree, LLC, Alcon, Recent Development
Table 76. Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Company Details
Table 77. Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Business Overview
Table 78. Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Neurotrophic Keratitis Product
Table 79. Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Revenue in Neurotrophic Keratitis Business (2016-2021) & (US$ Million)
Table 80. Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Recent Development
Table 81. CONTACARE, Company Details
Table 82. CONTACARE, Business Overview
Table 83. CONTACARE, Neurotrophic Keratitis Product
Table 84. CONTACARE, Revenue in Neurotrophic Keratitis Business (2016-2021) & (US$ Million)
Table 85. CONTACARE, Recent Development
Table 86. OHTO Pharmaceutical Co., Ltd., Company Details
Table 87. OHTO Pharmaceutical Co., Ltd., Business Overview
Table 88. OHTO Pharmaceutical Co., Ltd., Neurotrophic Keratitis Product
Table 89. OHTO Pharmaceutical Co., Ltd., Revenue in Neurotrophic Keratitis Business (2016-2021) & (US$ Million)
Table 90. OHTO Pharmaceutical Co., Ltd., Recent Development
Table 91. Pfizer, Inc., Company Details
Table 92. Pfizer, Inc., Business Overview
Table 93. Pfizer, Inc., Neurotrophic Keratitis Product
Table 94. Pfizer, Inc., Revenue in Neurotrophic Keratitis Business (2016-2021) & (US$ Million)
Table 95. Pfizer, Inc., Recent Development
Table 96. Neuroptika Company Details
Table 97. Neuroptika Business Overview
Table 98. Neuroptika Revenue in Neurotrophic Keratitis Business (2016-2021) & (US$ Million)
Table 99. Neuroptika Recent Development
Table 100. Santen Pharmaceutical Co., Ltd., Company Details
Table 101. Santen Pharmaceutical Co., Ltd., Business Overview
Table 102. Santen Pharmaceutical Co., Ltd., Neurotrophic Keratitis Product
Table 103. Santen Pharmaceutical Co., Ltd., Revenue in Neurotrophic Keratitis Business (2016-2021) & (US$ Million)
Table 104. Santen Pharmaceutical Co., Ltd., Recent Development
Table 105. Johnson & Johnson, Company Details
Table 106. Johnson & Johnson, Business Overview
Table 107. Johnson & Johnson, Neurotrophic Keratitis Product
Table 108. Johnson & Johnson, Revenue in Neurotrophic Keratitis Business (2016-2021) & (US$ Million)
Table 109. Johnson & Johnson, Recent Development
Table 110. Grand Pharma (China) Co., Ltd., and Company Details
Table 111. Grand Pharma (China) Co., Ltd., and Business Overview
Table 112. Grand Pharma (China) Co., Ltd., and Neurotrophic Keratitis Product
Table 113. Grand Pharma (China) Co., Ltd., and Revenue in Neurotrophic Keratitis Business (2016-2021) & (US$ Million)
Table 114. Grand Pharma (China) Co., Ltd., and Recent Development
Table 115. Zhejiang CONBA Pharmaceutical Co., Ltd. Company Details
Table 116. Zhejiang CONBA Pharmaceutical Co., Ltd. Business Overview
Table 117. Zhejiang CONBA Pharmaceutical Co., Ltd. Neurotrophic Keratitis Product
Table 118. Zhejiang CONBA Pharmaceutical Co., Ltd. Revenue in Neurotrophic Keratitis Business (2016-2021) & (US$ Million)
Table 119. Zhejiang CONBA Pharmaceutical Co., Ltd. Recent Development
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurotrophic Keratitis Market Share by Type: 2020 VS 2027
Figure 2. Drugs Features
Figure 3. Surgical Intervention Features
Figure 4. Global Neurotrophic Keratitis Market Share by Application: 2020 VS 2027
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Neurotrophic Keratitis Report Years Considered
Figure 8. Global Neurotrophic Keratitis Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 9. Global Neurotrophic Keratitis Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Neurotrophic Keratitis Market Share by Regions: 2020 VS 2027
Figure 11. Global Neurotrophic Keratitis Market Share by Regions (2022-2027)
Figure 12. Global Neurotrophic Keratitis Market Share by Players in 2020
Figure 13. Global Top Neurotrophic Keratitis Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurotrophic Keratitis as of 2020
Figure 14. The Top 10 and 5 Players Market Share by Neurotrophic Keratitis Revenue in 2020
Figure 15. Global Neurotrophic Keratitis Revenue Market Share by Type (2016-2021)
Figure 16. Global Neurotrophic Keratitis Revenue Market Share by Type (2022-2027)
Figure 17. North America Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 18. North America Neurotrophic Keratitis Market Share by Type (2016-2027)
Figure 19. North America Neurotrophic Keratitis Market Share by Application (2016-2027)
Figure 20. North America Neurotrophic Keratitis Market Share by Country (2016-2027)
Figure 21. United States Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. Canada Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Europe Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Neurotrophic Keratitis Market Share by Type (2016-2027)
Figure 25. Europe Neurotrophic Keratitis Market Share by Application (2016-2027)
Figure 26. Europe Neurotrophic Keratitis Market Share by Country (2016-2027)
Figure 27. Germany Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. France Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. U.K. Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Italy Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Russia Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Nordic Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Asia-Pacific Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Neurotrophic Keratitis Market Share by Type (2016-2027)
Figure 35. Asia-Pacific Neurotrophic Keratitis Market Share by Application (2016-2027)
Figure 36. Asia-Pacific Neurotrophic Keratitis Market Share by Region (2016-2027)
Figure 37. China Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Japan Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. South Korea Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Southeast Asia Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. India Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Australia Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Latin America Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Neurotrophic Keratitis Market Share by Type (2016-2027)
Figure 45. Latin America Neurotrophic Keratitis Market Share by Application (2016-2027)
Figure 46. Latin America Neurotrophic Keratitis Market Share by Country (2016-2027)
Figure 47. Mexico Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Brazil Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Middle East & Africa Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Neurotrophic Keratitis Market Share by Type (2016-2027)
Figure 51. Middle East & Africa Neurotrophic Keratitis Market Share by Application (2016-2027)
Figure 52. Middle East & Africa Neurotrophic Keratitis Market Share by Country (2016-2027)
Figure 53. Turkey Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Saudi Arabia Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. UAE Neurotrophic Keratitis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Dompe farmaceutici S.p.A., Revenue Growth Rate in Neurotrophic Keratitis Business (2016-2021)
Figure 57. Allergan, Revenue Growth Rate in Neurotrophic Keratitis Business (2016-2021)
Figure 58. ReGenTree, LLC, Alcon, Revenue Growth Rate in Neurotrophic Keratitis Business (2016-2021)
Figure 59. Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Revenue Growth Rate in Neurotrophic Keratitis Business (2016-2021)
Figure 60. CONTACARE, Revenue Growth Rate in Neurotrophic Keratitis Business (2016-2021)
Figure 61. OHTO Pharmaceutical Co., Ltd., Revenue Growth Rate in Neurotrophic Keratitis Business (2016-2021)
Figure 62. Pfizer, Inc., Revenue Growth Rate in Neurotrophic Keratitis Business (2016-2021)
Figure 63. Neuroptika Revenue Growth Rate in Neurotrophic Keratitis Business (2016-2021)
Figure 64. Santen Pharmaceutical Co., Ltd., Revenue Growth Rate in Neurotrophic Keratitis Business (2016-2021)
Figure 65. Johnson & Johnson, Revenue Growth Rate in Neurotrophic Keratitis Business (2016-2021)
Figure 66. Grand Pharma (China) Co., Ltd., and Revenue Growth Rate in Neurotrophic Keratitis Business (2016-2021)
Figure 67. Zhejiang CONBA Pharmaceutical Co., Ltd. Revenue Growth Rate in Neurotrophic Keratitis Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

---